|Blue Cohosh||Boldenone||Boldine||Boldo||Bole, Armenian|
|Systematic (IUPAC) name|
|Legal status||℞ Prescription only|
|Excretion||59% (urine), 30% (faeces)|
|Mol. mass||367.50 g/mol|
Blonanserin (Lonasen) is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.
Blonanserin acts as a mixed 5-HT2A (Ki = 0.812 nM) and D2 receptor (Ki = 0.142 nM) antagonist and also exerts some blockade of α1-adrenergic receptors (Ki = 26.7 nM). It lacks significant affinity for numerous other sites including the 5-HT1A, 5-HT3, D1, α2-adrenergic, β-adrenergic, H1, and mACh receptors and the monoamine transporters, though it does possess low affinity for the sigma receptor (IC50 = 286 nM).
It has a relatively high affinity towards the 5-HT6 receptor perhaps underpinning its recently unveiled efficacy in treating the cognitive symptoms of schizophrenia.
|Receptor||Ki [nM] (Blonanserin)* ||Ki [nM] (N-deethylblonanserin)* |
|α1||26.7 (Rat brain)||206 (Rat receptor)|
|α2||530 (Rat cloned)||-|
* Towards human receptors unless otherwise specified.